Table 4.
Summary of adverse events by preferred term
| Adverse event | Moderate renal impairment | Normal renal function or mild renal impairment | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canagliflozin 100 mg (n = 12) | Canagliflozin 200 mg (n = 12) | Canagliflozin 100 mg (n = 12) | Canagliflozin 200 mg (n = 12) | |||||||||
| No. of events | No. of subjects | Incidence (%) | No. of events | No. of subjects | Incidence (%) | No. of events | No. of subjects | Incidence (%) | No. of events | No. of subjects | Incidence (%) | |
| Total | 3 | 3 | 25.0 | 1 | 1 | 8.3 | 3 | 2 | 16.7 | 4 | 3 | 25.0 |
| Constipation | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 | 0 | 0 | 0.0 |
| Diarrhea | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 | 0 | 0 | 0.0 |
| Nasopharyngitis | 1 | 1 | 8.3 | 1 | 1 | 8.3 | 0 | 0 | 0.0 | 1 | 1 | 8.3 |
| Blood CPK increased | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 |
| Blood creatinine increased | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 |
| Blood glucose increased | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 |
| Protein urine present | 1 | 1 | 8.3 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 |
| Back pain | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 1 | 1 | 8.3 | 0 | 0 | 0.0 |
| Pollakiuria | 1 | 1 | 8.3 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 |
CPK creatine phosphokinase